SCHEMBL5217451

SCHEMBL5217451

Cc1ccc2c(O)cc(F)c(F)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
OPRK1 P41145 1/20 0.49
MAPT P10636 2/20 0.45
METAP2 P50579 1/20 0.42
CTSB P07858 1/20 0.41
CTSH P09668 1/20 0.41
CCR1 P32246 1/20 0.39
RAB9A P51151 1/20 0.39
CCR5 P51681 1/20 0.39
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.33
HTT P42858 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
MYC P01106 1/20 0.33
MAX P61244 1/20 0.33
USP2 O75604 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883600 0.78 KMT2A (0.56) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL3799140 0.74 OPRK1 (0.50) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL16705095 0.74 OPRK1 (0.43) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL8673009 0.74 CCR1 (0.58) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL17361074 0.72 OPRK1 (0.48) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL3275602 0.72 KMT2A (0.77) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL22084269 0.71 KDM4E (0.42) KMT2AOPRK1MAPTMETAP2KDM4E
SCHEMBL4059605 0.71 CCR1 (0.39) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL7171554 0.71 KMT2A (0.74) KMT2AOPRK1MAPTMETAP2CTSB
SCHEMBL28898898 0.69 KMT2A (0.71) KMT2AOPRK1MAPTMETAP2CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1330460-B1 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2007-03-21 EP disclosed
US-6939871-B2 Benzoxazinone derivatives, their preparation and use SMITHKLINE BEECHAM P.L.C. (GB) 2005-09-06 US disclosed
US-20040063704-A1 Benzoxazinone derivatives, their preparation and use SMITHKLINE BEECHAM P.L.C (GB) 2004-04-01 US disclosed
EP-1330460-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM PLC (GB) 2003-07-30 EP disclosed
WO-2002034754-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063704-A1 Benzoxazinone derivatives, their preparation and use CYP2B6, CBR1, CYP2A6 KMT2A 2934/4885OPRK1 75/4885MAPT 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.